Nifurtimox (Lampit)

Generic Name: Nifurtimox

Nifurtimox is a medication used to treat Chagas disease and sleeping sickness. For sleeping sickness it is used together with eflornithine in nifurtimox-eflornithine combination treatment. In Chagas disease it is a second line option to benznidazole. It is given by mouth.


Common side effects include abdominal pain, headache, nausea, and weight loss. There are concerns from animal studies that it may increase the risk of cancer but these concerns have not be found in human trials. Nifurtimox is not recommended in pregnancy or in those with significant kidney or liver problems. It is a type of nitrofuran.

No health feed found.

Nifurtimox forms a nitro-anion radical metabolite that reacts with nucleic acids of the parasite causing significant break down of DNA. Its mechanism is similar to that proposed for the antibacterial action of nitrofuran agents. Nifurtimox undergoes reduction and creates oxygen radicals such as superoxide. These radicals are toxic to T. cruzi. Mammalian cells are protected by presence of catalase, glutathione, peroxidases, and superoxide dismutase. Accumulation of hydrogen peroxide to cytotoxic levels results in parasite death.

Nifurtimox has been used to treat Chagas disease, when it is given for 30 to 60 days. However, long term use of Nifurtimox does increase chances of adverse events like gastrointestinal and neurological side effects. Due to the low tolerance and completion rate of Nifurtimox, benznidazole is now being more considered for those who have Chagas disease and require long term treatment.

Nifurtimox has also been used to treat African trypanosomiasis (sleeping sickness), and is active in the second stage of the disease (central nervous system involvement). When nifurtimox is given on its own, about half of all patients will relapse, but the combination of melarsoprol with nifurtimox appears to be efficacious. Trials are awaited comparing melarsoprol/nifurtimox against melarsoprol alone for African sleeping sickness.

Combination therapy with eflornithine and nifurtimox is safer and easier than treatment with eflornithine alone, and appears to be equally or more effective. It has been recommended as first-line treatment for second-stage African trypanosomiasis

Anorexia (50-60% can limit completion of therapy)

Frequency Not Defined






Memory impairment


Sleep disorder




Pruritic dermatitis





Pulmonary infiltrates

Pleural effusion (rare)

Adult Dosage Forms & Strengths


  • 30mg
  • 120mg

Pediatric Dosage Forms & Strengths


  • 30mg
  • 120mg

Gastrointestinal complaints include nausea, vomiting, abdominal pain, anorexia, and weight loss. Possible neurologic symptoms include insomnia, twitching, restlessness, paraesthesias, disorientation, and seizures. Rashes also occur. These symptoms generally disappear when the dosage is reduced or therapy is stopped.

Active or history of peripheral neuropathy

Active or history of seizures & cerebral impairment, such as behavioral disorders, epilepsy, or psychoses

Hepatic impairment

Renal impairment

Share Your Opinion

Please fill the details

Did you find this helpful?

Your feedback will help us improve the product

Disclaimer :

The texts and materials and any other information published on this site serve a purely informative purpose, and have no official or legal status in the form they are published here. We do not guarantee any authenticity to the information provided here, kindly confirm the exactness of the content published here from relevant sources before you act on any information provided on this site.

Check your area pincode

Sorry, right now we are not available in your area

Send Your Message


By signing up, I agree to terms